Technical Analysis for INCY - Incyte Corporation
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Fell Below 20 DMA | Bearish | 0.41% | |
| Down 3 Days in a Row | Weakness | 0.41% | |
| Down 4 Days in a Row | Weakness | 0.41% | |
| MACD Bearish Signal Line Cross | Bearish | -0.78% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -0.78% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -0.78% | |
| Down 3 Days in a Row | Weakness | -0.78% | |
| Overbought Stochastic | Strength | -1.43% | |
| NR7 | Range Contraction | -3.53% |
| Alert | Time |
|---|---|
| 20 DMA Resistance | about 8 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
| Up 2% | about 10 hours ago |
| Up 1% | about 10 hours ago |
| Rose Above 20 DMA | about 11 hours ago |
Get a Trading Sidekick!
- Earnings date: 07/30/2024
Incyte Corporation Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; Phase II trial for essential thrombocythemia; Phase II trial for pancreatic cancer; Phase I/II trial to treat solid tumors/other hematologic malignancies, as well as baricitinib, a JAK inhibitor, which is Phase III trial for rheumatoid srthritis, Phase IIb trial for psoriasis, and Phase II trial for diabetic nephropathy. The company's products in pipeline also comprise INCB28060 and INCB24360, which are Phase II clinical trial products for the treatment of solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: S&P 500 Biopharmaceutical Nasdaq 100 Solid Tumors Inflammation Organic Compounds Chemical Compounds Pancreatic Cancer Psoriasis Hematologic Malignancies Diabetic Nephropathy Clinical Trial Product Myelofibrosis Clinical Trial Products Janus Kinase Inhibitor Morpholines Nitriles Polycythemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 67.365 |
| 52 Week Low | 50.27 |
| Average Volume | 3,977,142 |
| 200-Day Moving Average | 57.85 |
| 50-Day Moving Average | 57.29 |
| 20-Day Moving Average | 60.94 |
| 10-Day Moving Average | 62.12 |
| Average True Range | 1.41 |
| RSI (14) | 54.13 |
| ADX | 34.59 |
| +DI | 25.02 |
| -DI | 18.61 |
| Chandelier Exit (Long, 3 ATRs) | 60.08 |
| Chandelier Exit (Short, 3 ATRs) | 61.02 |
| Upper Bollinger Bands | 64.32 |
| Lower Bollinger Band | 57.55 |
| Percent B (%b) | 0.49 |
| BandWidth | 11.12 |
| MACD Line | 1.17 |
| MACD Signal Line | 1.46 |
| MACD Histogram | -0.2867 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 63.30 | ||||
| Resistance 3 (R3) | 63.40 | 62.70 | 62.90 | ||
| Resistance 2 (R2) | 62.70 | 62.08 | 62.65 | 62.76 | |
| Resistance 1 (R1) | 61.78 | 61.70 | 62.24 | 61.68 | 62.62 |
| Pivot Point | 61.08 | 61.08 | 61.31 | 61.03 | 61.08 |
| Support 1 (S1) | 60.16 | 60.46 | 60.62 | 60.06 | 59.12 |
| Support 2 (S2) | 59.46 | 60.08 | 59.41 | 58.98 | |
| Support 3 (S3) | 58.54 | 59.46 | 58.85 | ||
| Support 4 (S4) | 58.44 |
